| dc.relation | 1.Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing
differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte
colony-stimulating factor. J Biol Chem 1983; (258): 9017–23.
2.Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski
J, Lu H, Chen KK, et al. Recombinant human granulocyte colony-stimulating factor: effects
on normal and leukemic myeloid cells. Science 1986; (4746): 61–5.
3.Nicola NA, Peterson L. Identification of distinct receptors for two hemopoietic growth factors
(Granulocyte colony-stimulating Factor and Multipotential Colony-stimulating factor) by
chemical cross-linking. J Biol Chem 1986; (26): 12384-12389.
4.Marino VJ, Roguin LP. The granulocyte colony stimulating factor (G-CSF) activates
Jak/STAT and MAPK pathways in a trophoblastic cell line. J Cell Biochem. 2008; (5):1512-
23.
5.Hu Z, Chen Z, Wang Y, Jiang J, Tse G, Xu W, Ge J, Sun B. Effects of granulocyte
colonystimulating factor on rabbit carotid and porcine heart models of chronic obliterative
arterial disease. Mol Med Rep. 2019;(6):4569-4578.
6.Rosenkranz K, Meier C. Umbilical cord blood cell transplantation after brain ischemia--from
recovery of function to cellular mechanisms. Ann Anat. 2011;193(4):371-9.
7.Sörgel F1, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar
granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;(6):347-57
8.Gascon P1, Fuhr U, Sörgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S,
Muenzberg M. Development of a new G-CSF product based on biosimilarity assessment.
Ann Oncol. 2010;(7): 1419-29.
9.Rugo HS1, Linton KM2, Cervi P3, Rosenberg JA4, Jacobs I5. A clinician's guide to
biosimilars in oncology. Cancer Treat Rev. 2016;(46):73-9.
10.Ludwig H1, Bokemeyer C2, Aapro M3, Boccadoro M4, Gascón P5, Denhaerynck K6,7
Krendyukov A8, Abraham I6,9,10,11, MacDonald K6. Chemotherapy-induced
neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors
11.versus hematological malignancies: MONITOR-GCSF study. Future Oncol. 2019;(8):897-
907.
12.Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with
granulocyte colony-stimulating factor. Curr Opin Hematol 2002; (9):183-189.
13.Gluckman E1, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A,
Esperou H, Thierry D, Socie G, Lehn P, et al. Hematopoietic reconstitution in a patient with
Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J
Med. 1989;(17):1174-8.
14.Hordyjewska A, Popiołek Ł, Horecka A. Characteristics of hematopoietic stem cells of
umbilical cord blood. Cytotechnology. 2015;(3):387-96.
15.Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative
medicine. J Cell Physiol. 2007;(2):341–7.
16.Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of
multipotent mesenchymal stromal cells-The international society for cellular therapy (ISCT)
working proposal. Cytotherapy 2013;15(9):1054–61.
17.Patricia Flores-Guzmán, Verónica Fernández-Sánchez, Héctor Mayani. Concise Review:
Ex Vivo Expansion of Cord Blood-Derived Hematopoietic Stem and Progenitor Cells: Basic
Principles, Experimental Approaches, and Impact in Regenerative Medicine. Stem Cells
Translational Medicine. 2013; 2:830–838
18.Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic
stem/progenitor cells. Stem Cells. 1998;16(3):153-65.
19.Caplan AI. All MSCs Are Pericytes?. Cell Stem Cell. 2008;3(3):229–30.
20.Eirin A, Zhu X, Krier J, Tang H. Adipose tissue‐Derived Mesenchymal Stem Cells Improve
Revascularization Outcomes to Restore Renal Function in Swine Atherosclerotic Renal
Artery Stenosis. Stem Cells. 2012;30(5):1030–41.
21.Alvarez-Viejo M. CD271 as a marker to identify mesenchymal stem cells from diverse
sources before culture. World J Stem Cells. 2015;7(2):470-476.
22.Oppliger B, Joerger-Messerli MS, Simillion C, Mueller M, Surbek D V., Schoeberlein A.
Mesenchymal stromal cells from umbilical cord Wharton’s jelly trigger oligodendroglial differentiation in neural progenitor cells through cell-to-cell contact. Cytotherapy.
2017;19(7):829–38.
23.Pikuła M, Marek-Trzonkowska N, Wardowska A, Renkielska A, Trzonkowski P. Adipose
tissue-derived stem cells in clinical applications. Expert Opin Biol Ther. 2013;13(10):1357–
70.
24.Shin T-H, Kim H-S, Choi S, Kang K-S. Mesenchymal Stem Cell Therapy for Inflammatory
Skin Diseases: Clinical Potential and Mode of Action. Int J Mol Sci. 2017;18(2):244.
25.Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a
novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord
blood. Blood. 2004;104(9):2752-60.
26.Pelosi E1, Castelli G, Testa U. Human umbilical cord is a unique and safe source of various
types of stem cells suitable for treatment of hematological diseases and for regenerative
medicine. Blood Cells Mol Dis. 2012;49(1):20-8.
27.Zuk PA1, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK,
Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol
Biol Cell. 2002;13(12):4279-95.
28.Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal
criteria for defining multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
29.Chamberlain, G., Fox, J., Ashton, B. and Middleton, J. Concise review: mesenchymal stem
cells: their phenotype, differentiation capacity, immunological features, and potential for
homing. Stem cells. 2007; (11): 2739–274.
30.Yoo KH1, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE, Kim YJ, Yang SK, Jung
HL, Sung KW, Kim CW, Koo HH. Comparison of immunomodulatory properties of
mesenchymal stem cells derived from adult human tissues. Cell. Immunol. 2009; (2): 150-
15.
31.Chen Y1, Shao JZ, Xiang LX, Dong XJ, Zhang GR. Mesenchymal stem cells: a promising
candidate in regenerative medicine. Int J Biochem Cell Biol. 2008;40(5):815-20
32.Rasmusson. IImmune modulation by mesenchymal stem cells. Exp Cell Res. 2006;
(12):2169-79
33.Synnestvedt K1, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen
KR, Thompson LF, Colgan SP. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible
factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 2002; 110(7):
993–1002.
34.Fiegel HC, Kaifi JT, Quaas A, Varol E, Krickhahn A, Metzger R, et al. Lack of Thy1 (CD90)
expression in neuroblastomas is correlated with impaired survival. Pediatr Surg Int.
2008;24(1):101–5.
35.Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful
therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene
2003;22(42):6557–63.
36.Tsukamoto AS1, Reading C, Carella A, Frassoni F, Gorin C, LaPorte J, Negrin R, Blume K,
Cunningham I, Deisseroth A, et al. Biological characterization of stem cell present in
mobilized peripheral blood of CML patients. Bone Marrow Transplant. 1994; (14) suppl
3:S25-32.
37.Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing
differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte
colony-stimulating factor. J Biol Chem. 1983;258(14):9017-23.
38.Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, et al. Purification and
biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
Proc Natl Acad Sci U S A. 1985;82(5):1526-30.
39.Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, et al. Molecular
cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature.
1986;319(6052):415-8.
40.Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant
human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.
Science. 1986;232(4746):61-5.
41.Falkenburg JH, Harrington MA, de Paus RA, Walsh WK, Daub R, Landegent JE, et al.
Differential transcriptional and posttranscriptional regulation of gene expression of the
colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts.
Blood. 1991;78(3):658-65.
42.Ernst TJ, Ritchie AR, Demetri GD, Griffin JD. Regulation of granulocyte- and monocytecolony
stimulating factor mRNA levels in human blood monocytes is mediated primarily at
a post-transcriptional level. J Biol Chem. 1989;264(10):5700-3.
43.Dunn SM, Coles LS, Lang RK, Gerondakis S, Vadas MA, Shannon MF. Requirement for
nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor
necrosis factor response region of the granulocyte colony-stimulating factor promoter.
Blood. 1994;83(9):2469-79.
44.Nishizawa M, Tsuchiya M, Watanabe-Fukunaga R, Nagata S. Multiple elements in the
promoter of granulocyte colony-stimulating factor gene regulate its constitutive expression
in human carcinoma cells. J Biol Chem. 1990;265(10):5897-902.
45.Nishizawa M, Nagata S. Regulatory elements responsible for inducible expression of the
granulocyte colony-stimulating factor gene in macrophages. Mol Cell Biol. 1990;10(5):2002-
11.
46.Pradervand S, Maurya MR, Subramaniam S. Identification of signaling components
required for the prediction of cytokine release in RAW 264.7 macrophages. Genome Biol.
2006;7(2):R11.
47.Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin
17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1
and 2 lineages. Nat Immunol. 2005;6(11):1123-32.
48.Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan
nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+
T helper cells. Cell. 2006;126(6):1121-33.
49.Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages
and dendritic cells differentially induce regulatory and interleukin 17-producing T cell
responses. Nat Immunol. 2007;8(10):1086-94.
50.Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al.
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte
colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med.
2001;194(4):519-27.
51.Schwarzenberger P, Huang W, Ye P, Oliver P, Manuel M, Zhang Z, et al. Requirement of
endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated
granulopoiesis. J Immunol. 2000;164(9):4783-9.
52.Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic
neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285-94.
53.Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23
drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med.
2005;201(2):233-40.
54.Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin
17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1
and 2 lineages. Nat Immunol. 2005;6(11):1123-32.
55.Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular
mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine.
2008;42(3):277-88.
56.Larsen A, Davis T, Curtis BM, Gimpel S, Sims JE, Cosman D, et al. Expression cloning of
a human granulocyte colony-stimulating factor receptor: a structural mosaic of
hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med.
1990;172(6):1559-70.
57.Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily.
Proc Natl Acad Sci U S A. 1990;87(18):6934-8.
58.Tamada T, Honjo E, Maeda Y, Okamoto T, Ishibashi M, Tokunaga M, et al. Homodimeric
cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor
signaling complex. Proc Natl Acad Sci U S A. 2006;103(9):3135-40.
59.Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, et al. Efficiency of signalling through
cytokine receptors depends critically on receptor orientation. Nature. 1998;395(6701):511-6.
60.Aritomi M, Kunishima N, Okamoto T, Kuroki R, Ota Y, Morikawa K. Atomic structure of the
GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Nature.
1999;401(6754):713-7.
61.Nicola NA, Peterson L. Identification of distinct receptors for two hemopoietic growth factors
(granulocyte colony-stimulating factor and multipotential colony-stimulating factor) by
chemical cross-linking. J Biol Chem. 1986;261(26):12384-9.
62.Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic
common myeloid progenitors. Proc Natl Acad Sci U S A. 2002;99(18):11872-7.
63.Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF prevents cardiac
remodeling after myocardial infarction by activating the Jak-Stat pathway in
cardiomyocytes. Nat Med. 2005;11(3):305-11.
64.Fukunaga R, Ishizaka-Ikeda E, Seto Y, Nagata S. Expression cloning of a receptor for
murine granulocyte colony-stimulating factor. Cell. 1990;61(2):341-50.
65.Kluth SM, Buchheiser A, Houben AP, Geyh S, Krenz T, Radke TF, et al. DLK-1 as a marker
to distinguish unrestricted somatic stem cells and mesenchymal stromal cells in cord blood.
Stem Cells Dev. 2010;19(10):1471-83.
66.Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, Layton JE. Tyrosine kinase
JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both
become tyrosine-phosphorylated after receptor activation. Proc Natl Acad Sci U S A.
1994;91(8):2985-8.
67.Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J. Rapid activation of the STAT3
transcription factor by granulocyte colony-stimulating factor. Blood. 1994;84(6):1760-4.
68.Ziegler SF, Bird TA, Morella KK, Mosley B, Gearing DP, Baumann H. Distinct regions of the
human granulocyte-colony-stimulating factor receptor cytoplasmic domain are required for
proliferation and gene induction. Mol Cell Biol. 1993;13(4):2384-90.
69.Nicholson SE, Starr R, Novak U, Hilton DJ, Layton JE. Tyrosine residues in the granulocyte
colony-stimulating factor (G-CSF) receptor mediate G-CSF-induced differentiation of
murine myeloid leukemic (M1) cells. J Biol Chem. 1996;271(43):26947-53.
70.Zhu QS, Robinson LJ, Roginskaya V, Corey SJ. G-CSF-induced tyrosine phosphorylation
of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not
proliferative, responses. Blood. 2004;103(9):3305-12.
71.Akbarzadeh S, Ward AC, McPhee DO, Alexander WS, Lieschke GJ, Layton JE. Tyrosine
residues of the granulocyte colony-stimulating factor receptor transmit proliferation and
differentiation signals in murine bone marrow cells. Blood. 2002;99(3):879-87.
72.Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, El Kasmi KC, et al. STAT3
governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood.
2006;108(12):3682-90.
73.Grishin A, Sinha S, Roginskaya V, Boyer MJ, Gomez-Cambronero J, Zuo S, et al.
Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways
for G-CSF. Oncogene. 2000;19(1):97-105.
74.Chen C, Huang X, Atakilit A, Zhu QS, Corey SJ, Sheppard D. The Integrin alpha9beta1
contributes to granulopoiesis by enhancing granulocyte colony-stimulating factor receptor
signaling. Immunity. 2006;25(6):895-906.
75.Tapley P, Shevde NK, Schweitzer PA, Gallina M, Christianson SW, Lin IL, et al. Increased
G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient
viable motheaten mice. Exp Hematol. 1997;25(2):122-31
76.Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, et al. SOCS3 is a critical
physiological negative regulator of G-CSF signaling and emergency granulopoiesis.
Immunity. 2004;20(2):153-65.
77.Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute
myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93(2):440-
6.
78.Shimoda K, Feng J, Murakami H, Nagata S, Watling D, Rogers NC, et al. Jak1 plays an
essential role for receptor phosphorylation and Stat activation in response to granulocyte
colony-stimulating factor. Blood. 1997;90(2):597-604.
79.Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the
Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced
biologic responses. Cell. 1998;93(3):373-83.
80.Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is
essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-95.
81.Fukunaga R, Ishizaka-Ikeda E, Nagata S. Growth and differentiation signals mediated by
different regions in the cytoplasmic domain of granulocyte colony-stimulating factor
receptor. Cell. 1993;74(6):1079-87.
82.Nicholson SE, Novak U, Ziegler SF, Layton JE. Distinct regions of the granulocyte colonystimulating
factor receptor are required for tyrosine phosphorylation of the signaling
molecules JAK2, Stat3, and p42, p44MAPK. Blood. 1995;86(10):3698-704.
83.Dong F, van Buitenen C, Pouwels K, Hoefsloot LH, Lowenberg B, Touw IP. Distinct
cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved
in induction of proliferation and maturation. Mol Cell Biol. 1993;13(12):7774-81.
84.Koning JP, Schelen AM, Dong F, van Buitenen C, Burgering BM, Bos JL, et al. Specific
involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in
signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. Blood.
1996;87(1):132-40.
85.Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS. The conserved box 1 motif of
cytokine receptors is required for association with JAK kinases. J Biol Chem.
1995;270(12):6523-30.
86.Yoshikawa A, Murakami H, Nagata S. Distinct signal transduction through the tyrosinecontaining
domains of the granulocyte colony-stimulating factor receptor. EMBO J.
1995;14(21):5288-96.
87.Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science.
2002;296(5573):1653-5.
88.Tian SS, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P. Multiple signaling pathways
induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5,
and/or STAT3 are required for regulation of three distinct classes of immediate early genes.
Blood. 1996;88(12):4435-44.
89.Koning JP, Soede-Bobok AA, Schelen AM, Smith L, van Leeuwen D, Santini V, et al.
Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human
granulocyte colony-stimulating factor receptor. Blood. 1998;91(6):1924-33.
90.Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP. Multiple signals mediate
proliferation, differentiation, and survival from the granulocyte colony-stimulating factor
receptor in myeloid 32D cells. J Biol Chem. 1999;274(21):14956-62.
91.Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of
Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction
and transformation. Nature. 1993;363(6424):45-51.
92.Corey SJ, Burkhardt AL, Bolen JB, Geahlen RL, Tkatch LS, Tweardy DJ. Granulocyte
colony-stimulating factor receptor signaling involves the formation of a three-component
complex with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci U S A.
1994;91(11):4683-7.
93.Ward AC, Monkhouse JL, Csar XF, Touw IP, Bello PA. The Src-like tyrosine kinase Hck is
activated by granulocyte colony-stimulating factor (G-CSF) and docks to the activated GCSF
receptor. Biochem Biophys Res Commun. 1998;251(1):117-23.
94.Dong F, Larner AC. Activation of Akt kinase by granulocyte colony-stimulating factor (GCSF):
evidence for the role of a tyrosine kinase activity distinct from the Janus kinases.
Blood. 2000;95(5):1656-62.
95.Mermel CH, McLemore ML, Liu F, Pereira S, Woloszynek J, Lowell CA, et al. Src family
kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood.
2006;108(8):2562-8.
96.Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immunol.
2006;7(4):333-7.
97.Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116(5):1195-201.
98.Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone
remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol. 2007;25:51-69.
99.Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from
the sympathetic nervous system regulate hematopoietic stem cell egress from bone
marrow. Cell. 2006;124(2):407-21.
100.Bautz F, Denzlinger C, Kanz L, Mohle R. Chemotaxis and transendothelial migration of
CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene
D4 are mediated by the 7-transmembrane receptor CysLT1. Blood. 2001;97(11):3433-40.
101.Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood.
2005;106(6):1901-10.
102.Rossi L, Manfredini R, Bertolini F, Ferrari D, Fogli M, Zini R, et al. The extracellular
nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood.
2007;109(2):533-42.
103.Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased
circulating hematopoietic and endothelial progenitor cells in the early phase of acute
myocardial infarction. Blood. 2005;105(1):199-206.
104.Lemoli RM, Catani L, Talarico S, Loggi E, Gramenzi A, Baccarani U, et al. Mobilization of
bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver
transplantation and liver resection. Stem Cells. 2006;24(12):2817-25.
105.Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic
mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and
the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004;103(1):110-
9.
106.Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the
CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization
induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187-96.
107.Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion
molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following
hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood.
2001;98(5):1289-97.
108.Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its
receptor: crystal structure of the complex. Science. 1992;255(5042):306-12.
109.Levesque JP, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, et al. Characterization
of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104(1):65-
72.
110.Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal GCSF-
induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol.
2003;31(11):1126-34.
111.Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, et al. Kinetic investigation
of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within
the chemokine family. J Biol Chem. 2001;276(32):29839-45.
112.Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, et al.
Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress
hematopoiesis. Nat Med. 2012;18(12):1786-96.
113.Juarez JG, Harun N, Thien M, Welschinger R, Baraz R, Pena AD, et al. Sphingosine-1-
phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by
CXCR4 antagonists in mice. Blood. 2012;119(3):707-16.
114.Golan K, Vagima Y, Ludin A, Itkin T, Cohen-Gur S, Kalinkovich A, et al. S1P promotes
murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-
1 release. Blood. 2012;119(11):2478-88.
115.Ratajczak MZ, Lee H, Wysoczynski M, Wan W, Marlicz W, Laughlin MJ, et al. Novel insight
into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that
directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level
in peripheral blood increases during mobilization due to activation of complement
cascade/membrane attack complex. Leukemia. 2010;24(5):976-85.
116.Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and
paracrine network. Nat Rev Immunol. 2005;5(7):560-70.
117.Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte
sequestration through S1P lyase inhibition and disruption of S1P gradients. Science.
2005;309(5741):1735-9.
118.Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of
lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate.
Science. 2007;316(5822):295-8.
119.Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, et al. The
sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates
lymphocyte trafficking in mice. J Clin Invest. 2012;122(4):1416-26.
120.Massberg S, Schaerli P, Knezevic-Maramica I, Kollnberger M, Tubo N, Moseman EA, et al.
Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and
peripheral tissues. Cell. 2007;131(5):994-1008.
121.Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, et al. G-CSF potently
inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood.
2005;106(9):3020-7.
122.Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade
endosteal components and promote mobilization of hematopoietic progenitor cells. Nat
Med. 2006;12(6):657-64.
123.Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY, et al. Diabetes
impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med.
2011;3(104):104ra1.
124.Shivtiel S, Kollet O, Lapid K, Schajnovitz A, Goichberg P, Kalinkovich A, et al. CD45
regulates retention, motility, and numbers of hematopoietic progenitors, and affects
osteoclast remodeling of metaphyseal trabecules. J Exp Med. 2008;205(10):2381-95.
125.Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, et al. Osteoclasts
are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med.
2011;208(11):2175-81.
126.Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al. Bone marrow
macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes
HSCs. Blood. 2010;116(23):4815-28.
127.Hirbe AC, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, et al.
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclastdependent
manner. Blood. 2007;109(8):3424-31.
128.Asada N, Katayama Y, Sato M, Minagawa K, Wakahashi K, Kawano H, et al. Matrixembedded
osteocytes regulate mobilization of hematopoietic stem/progenitor cells. Cell
Stem Cell. 2013;12(6):737-47.
129.Hanazono Y, Hosoi T, Kuwaki T, Matsuki S, Miyazono K, Miyagawa K, et al. Structural
analysis of the receptors for granulocyte colony-stimulating factor on neutrophils. Exp
Hematol. 1990;18(10):1097-103.
130.Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a
functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest.
1993;91(4):1310-3.
131.Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood.
1996;88(3):761-77.
132.Ward AC, Loeb DM, Soede-Bobok AA, Touw IP, Friedman AD. Regulation of granulopoiesis
by transcription factors and cytokine signals. Leukemia. 2000;14(6):973-90.
133.Shimizu T, Sugaya M, Nakano Y, Izutsu D, Mizukami Y, Okochi K, et al. Formulation study
for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets. Chem
Pharm Bull (Tokyo). 2003;51(10):1121-7.
134.Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, et al. Stem cell
mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve
cardiac regeneration after acute ST-elevation myocardial infarction: result of the doubleblind,
randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial.
Circulation. 2006;113(16):1983-92.
135.Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, et al. Effect of granulocyte
colony-stimulating factor treatment at a low dose but for a long duration in patients with
coronary heart disease. Circ J. 2006;70(4):430-7.
136.Sanchez-Ramos J, Song S, Cao C, Arendash G. The potential of hematopoietic growth
factors for treatment of Alzheimer's disease: a mini-review. BMC Neurosci. 2008;9 Suppl
2:S3.
137.Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, et al. Health
Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry
biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012;40(6):517-27.
138.Bonig H, Becker PS, Schwebig A, Turner M. Biosimilar granulocyte-colony-stimulating
factor for healthy donor stem cell mobilization: need we be afraid? Transfusion.
2015;55(2):430-9.
139.Mysler E, Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin
Rheumatol. 2012;31(9):1279-80.
140.Knezevic I. Evaluation of similar biotherapeutic products (SBPs): scientific principles and
their implementation. Biologicals. 2011;39(5):256-61.
141.Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality
attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2.
142.Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther.
2008;33(5):459-64.
143.Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus.
2009;2(Suppl_1):i27-i36.
144.Curigliano G, O'Connor DP, Rosenberg JA, Jacobs I. Biosimilars: Extrapolation for
oncology. Crit Rev Oncol Hematol. 2016;104:131-7.
145.Cesaro S, Chinello P, De Silvestro G, Marson P, Picco G, Varotto S, et al. Granulocyte
transfusions from G-CSF-stimulated donors for the treatment of severe infections in
neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer.
2003;11(2):101-6.
146.Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood.
1991;78(11):2791-808.
147.Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O'Connor M, et al. Treatment of
chemotherapy-induced neutropenia by subcutaneously administered granulocyte colonystimulating
factor with optimization of dose and duration of therapy. J Clin Oncol.
1989;7(10):1554-62.
148.Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic
factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives
neurogenesis. J Clin Invest. 2005;115(8):2083-98.
149.Su YC, Li SC, Hsu CK, Yu CC, Lin TJ, Lee CY, et al. G-CSF downregulates natural killer
cell-mediated cytotoxicity in donors for hematopoietic SCT. Bone Marrow Transplant.
2012;47(1):73-81.
150.Link DC. Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic
progenitor-cell mobilization. Semin Hematol. 2000;37(1 Suppl 2):25-32.
151.Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, et al. Advances in mobilization
for the optimization of autologous stem cell transplantation. Leuk Lymphoma.
2009;50(9):1412-21.
152.Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking
granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and
macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood.
1994;84(6):1737-46.
153.Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased
apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice.
Immunity. 1996;5(5):491-501.
154.Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of
granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88(8):2819-25.
155.Hara M, Yuasa S, Shimoji K, Onizuka T, Hayashiji N, Ohno Y, et al. G-CSF influences
mouse skeletal muscle development and regeneration by stimulating myoblast proliferation.
J Exp Med. 2011;208(4):715-27.
156.Takayama H, Miyake Y, Nouso K, Ikeda F, Shiraha H, Takaki A, et al. Serum levels of
platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic
factors for patients with fulminant hepatic failure. J Gastroenterol Hepatol. 2011;26(1):116-
21.
157.Dominguez JM, 2nd, Yorek MA, Grant MB. Combination therapies prevent the neuropathic,
proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats.
Diabetes. 2015;64(2):643-53
158.Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance.
Transplantation. 2007;84(1 Suppl):S26-30.
159.Grove JE, Bruscia E, Krause DS. Plasticity of bone marrow-derived stem cells. Stem Cells.
2004;22(4):487-500.
160.Murakami M, Hayashi Y, Iohara K, Osako Y, Hirose Y, Nakashima M. Trophic Effects and
Regenerative Potential of Mobilized Mesenchymal Stem Cells From Bone Marrow and
Adipose Tissue as Alternative Cell Sources for Pulp/Dentin Regeneration. Cell Transplant.
2015;24(9):1753-65.
161.Law P, Lane TA. Mobilization of allogeneic peripheral blood progenitor cells. Cancer Treat
Res. 2002;110:51-77.
162.Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, et al. Development
of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21(7):1419-
29.
163.Sorgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a
biosimilar granulocyte colony-stimulating factor with its reference product.
BioDrugs. 2010;24(6):347-57.
164.Ianotto JC, Tempescul A, Yan X, Delepine P, Le Calloch R, Hardy E, et al. Experience (1
year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow
Transplant. 2012;47(6):874-6.
165.Lefrere F, Brignier AC, Elie C, Ribeil JA, Bernimoulin M, Aoun C, et al. First experience of
autologous peripheral blood stem cell mobilization with biosimilar granulocyte colonystimulating
factor. Adv Ther. 2011;28(4):304-10.
166.Williams AF, Gagnon J. Neuronal cell Thy-1 glycoprotein: homology with immunoglobulin.
Science. 1982;216(4547):696-703.
167.Raff MC. Surface antigenic markers for distinguishing T and B lymphocytes in mice.
Transplant Rev. 1971;6:52-80.
168.Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon
regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J.
2006;20(8):1045-54.
169.James AW. Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic
Differentiation. Scientifica (Cairo). 2013;2013:684736.
170.Moraes DA, Sibov TT, Pavon LF, Alvim PQ, Bonadio RS, Da Silva JR, et al. A reduction in
CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells.
Stem Cell Res Ther. 2016;7(1):97.
171.Barker TH, Hagood JS. Getting a grip on Thy-1 signaling. Biochim Biophys Acta.
2009;1793(5):921-3.
172.Spychala J, Kitajewski J. Wnt and beta-catenin signaling target the expression of ecto-5'-
nucleotidase and increase extracellular adenosine generation. Exp Cell Res.
2004;296(2):99-108.
173.Hunsucker SA, Mitchell BS, Spychala J. The 5'-nucleotidases as regulators of nucleotide
and drug metabolism. Pharmacol Ther. 2005;107(1):1-30.
174.Takedachi M, Oohara H, Smith BJ, Iyama M, Kobashi M, Maeda K, et al. CD73-generated
adenosine promotes osteoblast differentiation. J Cell Physiol. 2012;227(6):2622-31.
175.Song SW, Chang W, Song BW, Song H, Lim S, Kim HJ, et al. Integrin-linked kinase is
required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic
myocardium. Stem Cells. 2009;27(6):1358-65.
176.Grailer JJ, Kodera M, Steeber DA. L-selectin: role in regulating homeostasis and cutaneous
inflammation. J Dermatol Sci. 2009;56(3):141-7
177.Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone
marrow stromal cells express a distinct set of biologically functional chemokine receptors.
Stem Cells. 2006;24(4):1030-41.
178.Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of
adipogenesis. Genes Dev. 2000;14(11):1293-307.
179.Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell
Biol. 2006;7(12):885-96.
180.Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW, et al. Regulation of
Wnt signaling during adipogenesis. J Biol Chem. 2002;277(34):30998-1004.
181.Prestwich TC, Macdougald OA. Wnt/beta-catenin signaling in adipogenesis and
metabolism. Curr Opin Cell Biol. 2007;19(6):612-7.
182.Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer
Res. 2007;13(14):4042-5
183.Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling
stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor
gamma. J Biol Chem. 2007;282(19):14515-24.
184.Keats EC, Dominguez JM, 2nd, Grant MB, Khan ZA. Switch from canonical to noncanonical
Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells. 2014;32(6):1649-
60.
185.He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/betacatenin
signaling: arrows point the way. Development. 2004;131(8):1663-77.
186.Christodoulides C, Laudes M, Cawthorn WP, Schinner S, Soos M, O'Rahilly S, et al. The
Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human
adipogenesis. J Cell Sci. 2006;119(Pt 12):2613-20.
187., Kuhl M. From individual Wnt pathways towards a Wnt signalling network. Philos Trans R
Soc Lond B Biol Sci. 2008;363(1495):1333-47.
188.Kuwabara M, Kakinuma Y, Katare RG, Ando M, Yamasaki F, Doi Y, et al. Granulocyte
colony-stimulating factor activates Wnt signal to sustain gap junction function through
recruitment of beta-catenin and cadherin. FEBS Lett. 2007;581(25):4821-30.
189.Kanazawa A, Tsukada S, Kamiyama M, Yanagimoto T, Nakajima M, Maeda S. Wnt5b
partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis
in 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 2005;330(2):505-10.
190.Sherman L, Sleeman J, Dall P, Hekele A, Moll J, Ponta H, et al. The CD44 proteins in
embryonic development and in cancer. Curr Top Microbiol Immunol. 1996;213 ( Pt 1):249-
69.
191.Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, et al. CD44 regulates
hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood.
1997;90(6):2217-33.
192.Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators.
Nat Rev Mol Cell Biol. 2003;4(1):33-45.
193.Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies
to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med.
1990;171(2):477-88.
194.Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in
vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42(4):659-68.
195.Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in
vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42(4):659-68.
196.Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer.
2010;46(7):1271-7.
197.Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface
receptor for hyaluronate. Cell. 1990;61(7):1303-13.
198.Sherman LS, Rizvi TA, Karyala S, Ratner N. CD44 enhances neuregulin signaling by
Schwann cells. J Cell Biol. 2000;150(5):1071-84.
199.Guilak F, Lott KE, Awad HA, Cao Q, Hicok KC, Fermor B, et al. Clonal analysis of the
differentiation potential of human adipose-derived adult stem cells. J Cell Physiol.
2006;206(1):229-37.
200.Matsumoto T, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, et al. Mature adipocytederived
dedifferentiated fat cells exhibit multilineage potential. J Cell Physiol.
2008;215(1):210-22.
201.Bourguignon LY, Peyrollier K, Gilad E, Brightman A. Hyaluronan-CD44 interaction with
neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and
ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation,
and cell migration in ovarian tumor cells. J Biol Chem. 2007;282(2):1265-80.
202.Lee SH, Jun HK, Lee HR, Chung CP, Choi BK. Antibacterial and lipopolysaccharide (LPS)-
neutralising activity of human cationic antimicrobial peptides against periodontopathogens.
Int J Antimicrob Agents. 2010;35(2):138-45.
203.Gold J, Valinski HM, Hanks AN, Ballen KK, Hsieh CC, Becker PS. Adhesion receptor
expression by CD34+ cells from peripheral blood or bone marrow grafts: correlation with
time to engraftment. Exp Hematol. 2006;34(5):680-7.
204.Day TD. The permeability of interstitial connective tissue and the nature of the interfibrillary
substance. J Physiol. 1952;117(1):1-8.
205.Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al.
Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J.
2011;278(9):1429-43.
206.Hascall VC, Majors AK, De La Motte CA, Evanko SP, Wang A, Drazba JA, et al. Intracellular
hyaluronan: a new frontier for inflammation? Biochim Biophys Acta. 2004;1673(1-2):3-12.
207.Lee S, Im SA, Yoo ES, Nam EM, Lee MA, Ahn JY, et al. Mobilization kinetics of CD34(+)
cells in association with modulation of CD44 and CD31 expression during continuous
intravenous administration of G-CSF in normal donors. Stem Cells. 2000;18(4):281-6.
208.Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle.
2006;5(21):2440-2.
209.Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, et al. Down-regulation of
the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to
unfavorable prognostic features. Am J Pathol. 2010;177(6):2886-97.
210.Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation
to cancer. J Leukoc Biol. 2010;88(6):1109-17.
211.Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrowderived
mesenchymal stem cells (MSCs) express hematopoietic cytokines and support
long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J
Hematother Stem Cell Res. 2000;9(6):841-8.
212.Keller DC, Du XX, Srour EF, Hoffman R, Williams DA. Interleukin-11 inhibits adipogenesis
and stimulates myelopoiesis in human long-term marrow cultures. Blood. 1993;82(5):1428-
35.
213.Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal
differentiation and induces proinflammatory gene expression and migration of human
keratinocytes. J Immunol. 2005;174(6):3695-702.
214.Van de Ven C, Ishizawa L, Law P, Cairo MS. IL-11 in combination with SLF and G-CSF or
GM-CSF significantly increases expansion of isolated CD34+ cell population from cord
blood vs. adult bone marrow. Exp Hematol. 1995;23(12):1289-95.
215.Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in
tumorigenesis. Nat Rev Cancer. 2011;11(1):23-34.
216.Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of pim-1 protein
kinase gene expression by interferon gamma and posttranscriptional effects on
costimulation with steel factor. Blood. 1995;85(12):3494-502.
217.Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase
promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112
gatekeeper site. FEBS Lett. 2004;571(1-3):43-9.
218.Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates
ASK1-mediated apoptosis. Oncogene. 2009;28(48):4261-71.
219.Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle
progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and
posttranscriptional levels. Cancer Res. 2008;68(13):5076-85.
220.Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin
Immunol. 2000;105(6 Pt 1):1063-70.
221.Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs
survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-
dependent pathway. Oncogene. 1999;18(27):4022-31.
222.Choy L, Skillington J, Derynck R. Roles of autocrine TGF-beta receptor and Smad signaling
in adipocyte differentiation. J Cell Biol. 2000;149(3):667-82.
223.Kawamura K, Chu CR, Sobajima S, Robbins PD, Fu FH, Izzo NJ, et al. Adenoviral-mediated
transfer of TGF-beta1 but not IGF-1 induces chondrogenic differentiation of human
mesenchymal stem cells in pellet cultures. Exp Hematol. 2005;33(8):865-72.
224.Tuli R, Tuli S, Nandi S, Huang X, Manner PA, Hozack WJ, et al. Transforming growth factorbeta-
mediated chondrogenesis of human mesenchymal progenitor cells involves Ncadherin
and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem.
2003;278(42):41227-36.
225.Huang AH, Stein A, Tuan RS, Mauck RL. Transient exposure to transforming growth factor
beta 3 improves the mechanical properties of mesenchymal stem cell-laden
cartilage constructs in a density-dependent manner. Tissue Eng Part A. 2009;15(11):3461-
72.
226.Manna PR, Chandrala SP, King SR, Jo Y, Counis R, Huhtaniemi IT, et al. Molecular
mechanisms of insulin-like growth factor-I mediated regulation of the steroidogenic acute
regulatory protein in mouse leydig cells. Mol Endocrinol. 2006;20(2):362-78.
227.Shiryaev A, Moens U. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5:
menage a trois or menage a quatre? Cell Signal. 2010;22(8):1185-92.
228.Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol.
1996;8(2):205-15.
229.Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131-
6.
230.Godeny MD, Sayeski PP. ERK1/2 regulates ANG II-dependent cell proliferation via
cytoplasmic activation of RSK2 and nuclear activation of elk1. Am J Physiol Cell Physiol.
2006;291(6):C1308-17.
231.Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, et al. Multiple synostoses syndrome
is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet. 2009;85(1):53-
63.
232.Behr B, Leucht P, Longaker MT, Quarto N. Fgf-9 is required for angiogenesis and
osteogenesis in long bone repair. Proc Natl Acad Sci U S A. 2010;107(26):11853-8.
233.268. 232 Hung IH, Yu K, Lavine KJ, Ornitz DM. FGF9 regulates early hypertrophic
chondrocyte differentiation and skeletal vascularization in the developing stylopod. Dev
Biol. 2007;307(2):300-13.
234.Govindarajan V, Overbeek PA. FGF9 can induce endochondral ossification in cranial
mesenchyme. BMC Dev Biol. 2006;6:7.
235.Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E, Leboy P, et al. Effects of
FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect,
inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone.
2005;36(2):254-66.
236.Soltanoff CS, Yang S, Chen W, Li YP. Signaling networks that control the lineage
commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr. 2009;19(1):1-
46.
237.Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK
phosphatases in control of the inflammatory response. J Immunol. 2006;177(11):7497-504.
238.Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase
phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev.
2008;60(3):261-310.
239.Holmes DA, Yeh JH, Yan D, Xu M, Chan AC. Dusp5 negatively regulates IL-33-mediated
eosinophil survival and function. EMBO J. 2015;34(2):218-35.
240.Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue
remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221-33.
241.Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, et al. Matrix
metalloproteinases are differentially expressed in adipose tissue during obesity and
modulate adipocyte differentiation. J Biol Chem. 2003;278(14):11888-96.
242.Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR. Modulation of adipose tissue
expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.
Diabetes. 2002;51(4):1093-101.
243.Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D. Matrix
metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler
Thromb Vasc Biol. 2002;22(3):374-9.
244.Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and
TIMPs. Cardiovasc Res. 2006;69(3):562-73.
245.Ambele MA, Dessels C, Durandt C, Pepper MS. Genome-wide analysis of gene expression
during adipogenesis in human adipose-derived stromal cells reveals novel patterns of gene
expression during adipocyte differentiation. Stem Cell Res. 2016;16 (3):725-34.
246.Kessenbrock K, Dijkgraaf GJ, Lawson DA, Littlepage LE, Shahi P, Pieper U, et al. A role for
matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling
pathway. Cell Stem Cell. 2013;13(3):300-13.
247.Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis
during mammary gland involution. J Cell Biol. 2001;152(4):693-703.
248.Croissandeau G, Chretien M, Mbikay M. Involvement of matrix metalloproteinases in the
adipose conversion of 3T3-L1 preadipocytes. Biochem J. 2002;364(Pt 3):739-46.
249.Montagnani C, Le Roux F, Berthe F, Escoubas JM. Cg-TIMP, an inducible tissue inhibitor
of metalloproteinase from the Pacific oyster Crassostrea gigas with a potential role in wound
healing and defense mechanisms(1). FEBS Lett. 2001;500(1-2):64-70.
250.Nagy B, Szelig L, Rendeki S, Loibl C, Rezman B, Lantos J, et al. Dynamic changes of matrix
metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 after burn injury. J Crit Care.
2015;30(1):162-6.
251.Fowell AJ, Collins JE, Duncombe DR, Pickering JA, Rosenberg WM, Benyon RC. Silencing
tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for
TIMP-1 in hepatic stellate cell proliferation. Biochem Biophys Res Commun.
2011;407(2):277-82.
252.Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in
mammary epithelial cells by extracellular matrix. Science. 1995;267(5199):891-3.
253.Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase
(TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells.
Blood. 1998;92(4):1342-9.
254.Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are
essential for the invasive capacity of human mesenchymal stem cells: differential regulation
by inflammatory cytokines. Blood. 2007;109(9):4055-63.
255.Glass C, Singla DK. Overexpression of TIMP-1 in embryonic stem cells attenuates adverse
cardiac remodeling following myocardial infarction. Cell Transplant. 2012;21(9):1931-44.
256.Zhang P, Li J, Qi Y, Tang X, Duan J, Liu L, et al. Tissue Inhibitor of Matrix
Metalloproteinases-1 Knockdown Suppresses the Proliferation of Human Adipose-Derived
Stem Cells. Stem Cells Int. 2016;2016:4761507.
257.Bernot D, Barruet E, Poggi M, Bonardo B, Alessi MC, Peiretti F. Down-regulation of tissue
inhibitor of metalloproteinase-3 (TIMP-3) expression is necessary for adipocyte
differentiation. J Biol Chem. 2010;285(9):6508-14.
258.Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases
organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17(23):2054-60.
259.Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain
transcription factor. Genes Dev. 2008;22(23):3320-34.
260.Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like
kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene.
2005;24(12):2076-86.
261.Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, et al. Structural basis of YAP
recognition by TEAD4 in the hippo pathway. Genes Dev. 2010;24(3):290-300.
262.Chen CL, Gajewski KM, Hamaratoglu F, Bossuyt W, Sansores-Garcia L, Tao C, et al. The
apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. Proc
Natl Acad Sci U S A. 2010;107(36):15810-5.
263.Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo
transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell.
2011;147(4):759-72.
264.Das Thakur M, Feng Y, Jagannathan R, Seppa MJ, Skeath JB, Longmore GD. Ajuba LIM
proteins are negative regulators of the Hippo signaling pathway. Curr Biol. 2010;20(7):657-
62.
265.Densham RM, O'Neill E, Munro J, Konig I, Anderson K, Kolch W, et al. MST kinases monitor
actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to
regulate p21Waf1/Cip1 stability. Mol Cell Biol. 2009;29(24):6380-90.
266.Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a
universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120-33.
267.Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ
in mechanotransduction. Nature. 2011;474(7350):179-83.
268.Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and
neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01
(PEG-r-metHu G-CSF). Clin Cancer Res. 2001;7(7):2085-90.
269.Sorgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar
filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and
pharmacokinetics. BioDrugs. 2015;29(2):123-31.
270.Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: the
advent of toxicogenomics. Mol Carcinog. 1999;24(3):153-9.
271.Chen M, Zhang M, Borlak J, Tong W. A decade of toxicogenomic research and its
contribution to toxicological science. Toxicol Sci. 2012;130(2):217-28.
272.Goetz AK, Singh BP, Battalora M, Breier JM, Bailey JP, Chukwudebe AC, et al. Current and
future use of genomics data in toxicology: opportunities and challenges for regulatory
applications. Regul Toxicol Pharmacol. 2011;61(2):141-53.
273.Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev
Cell Dev Biol. 1995;11:35-71.
274.Rosenkranz K, Meier C. Umbilical cord blood cell transplantation after brain ischemia--from
recovery of function to cellular mechanisms. Ann Anat. 2011;193(4):371-9.
275.Yang WZ, Zhang Y, Wu F, Min WP, Minev B, Zhang M, et al. Safety evaluation of allogeneic
umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med.
2010;8:75.
276.Sorg RV, Andres S, Kogler G, Fischer J, Wernet P. Phenotypic and functional comparison
of monocytes from cord blood and granulocyte colony-stimulating factor-mobilized
apheresis products. Exp Hematol. 2001;29(11):1289-94.
277.Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic
stem/progenitor cells. Stem Cells. 1998;16(3):153-65.
278.Secco M, Zucconi E, Vieira NM, Fogaca LL, Cerqueira A, Carvalho MD, et al. Multipotent
stem cells from umbilical cord: cord is richer than blood! Stem Cells. 2008;26(1):146-50.
279.Zuba-Surma EK, Klich I, Greco N, Laughlin MJ, Ratajczak J, Ratajczak MZ. Optimization of
isolation and further characterization of umbilical-cord-blood-derived very small embryonic/
epiblast-like stem cells (VSELs). Eur J Haematol. 2010;84(1):34-46.
280.Domanska-Janik K, Buzanska L, Lukomska B. A novel, neural potential of nonhematopoietic
human umbilical cord blood stem cells. Int J Dev Biol. 2008;52(2-3):237-48.
281.Domanska-Janik K, Habich A, Sarnowska A, Janowski M. Neural commitment of cord blood
stem cells (HUCB-NSC/NP): therapeutic perspectives. Acta Neurobiol Exp (Wars).
2006;66(4):279-91.
282.Pan L, Delmonte J, Jr., Jalonen CK, Ferrara JL. Pretreatment of donor mice with
granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine
production and reduces severity of experimental graft-versus-host disease. Blood.
1995;86(12):4422-9.
283.Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, et al. Effect of
granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in
human volunteers. Blood. 1995;85(9):2482-9.
284.Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell
proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized
peripheral blood mononuclear cells. Blood. 1997;89(5):1629-34.
285.Reyes E, Garcia-Castro I, Esquivel F, Hornedo J, Cortes-Funes H, Solovera J, et al.
Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated
T-cell proliferative response. Br J Cancer. 1999;80(1-2):229-35.
286.Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express
functional receptors for granulocyte colony-stimulating factor that mediate suppression of
monokines and interferon-gamma. Blood. 2000;95(1):270-6.
287.Suzuki K, Hino M, Hato F, Tatsumi N, Kitagawa S. Cytokine-specific activation of distinct
mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by
granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor,
and tumor necrosis factor-alpha. Blood. 1999;93(1):341-9.
288.Akbarzadeh S, Layton JE. Granulocyte colony-stimulating factor receptor: structure and
function. Vitam Horm. 2001;63:159-94.
289.Carvalho TT, Flauzino T, Otaguiri ES, Batistela AP, Zarpelon AC, Cunha TM, et al.
Granulocyte-colony stimulating factor (G-CSF) induces mechanical hyperalgesia via spinal
activation of MAP kinases and PI3K in mice. Pharmacol Biochem Behav. 2011;98(2):188-
95.
290.Kolsch V, Charest PG, Firtel RA. The regulation of cell motility and chemotaxis by
phospholipid signaling. J Cell Sci. 2008;121(Pt 5):551-9.
291.Shirvaikar N, Marquez-Curtis LA, Shaw AR, Turner AR, Janowska-Wieczorek A. MT1-MMP
association with membrane lipid rafts facilitates G-CSF--induced hematopoietic
stem/progenitor cell mobilization. Exp Hematol. 2010;38(9):823-35.
292.Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J.
Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix
metalloproteinase-dependent melanoma cell invasion. Cancer Res. 2006;66(1):248-58.
293.Marquez-Curtis LA, Turner AR, Sridharan S, Ratajczak MZ, Janowska-Wieczorek A. The
ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes. Stem
Cell Rev. 2011;7(3):590-607.
294.Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I
receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17(3):1595-606.
295.Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue
regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877-83.
296.Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD
couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231-41.
297.Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, et al. Beta interferon
and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-
dependent pathway. Mol Cell Biol. 1997;17(7):3833-40.
298.Sokac AM, Schietroma C, Gundersen CB, Bement WM. Myosin-1c couples assembling
actin to membranes to drive compensatory endocytosis. Dev Cell. 2006;11(5):629-40.
299.Furmento VA, Marino J, Blank VC, Cayrol MF, Cremaschi GA, Aguilar RC, et al.
Granulocyte colony-stimulating factor (G-CSF) upregulates beta1 integrin and increases
migration of human trophoblast Swan 71 cells via PI3K and MAPK activation. Exp Cell Res.
2016;342(2):125-34.
300.Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, et al. Proline-rich tyrosine kinase 2
(Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through
c-Src/ERK activation. Carcinogenesis. 2008;29(11):2096-105.
301.Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular
signalling. Cell Signal. 2000;12(3):123-33.
302.Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT.
Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent
binding of pp60src. Mol Cell Biol. 1994;14(3):1680-8.
303.Xing Z, Chen HC, Nowlen JK, Taylor SJ, Shalloway D, Guan JL. Direct interaction of v-Src
with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell.
1994;5(4):413-21.
304.Reiske HR, Kao SC, Cary LA, Guan JL, Lai JF, Chen HC. Requirement of
phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol
Chem. 1999;274(18):12361-6.
305.Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of
cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56-68.
306.Vemula S, Ramdas B, Hanneman P, Martin J, Beggs HE, Kapur R. Essential role for focal
adhesion kinase in regulating stress hematopoiesis. Blood. 2010;116(20):4103-15.
307.Greaves DR, Wang W, Dairaghi DJ, Dieu MC, Saint-Vis B, Franz-Bacon K, et al. CCR6, a
CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is
highly expressed in human dendritic cells. J Exp Med. 1997;186(6):837-44.
308.Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. CC-chemokine receptor 6
is expressed on diverse memory subsets of T cells and determines responsiveness to
macrophage inflammatory protein 3 alpha. J Immunol. 1999;162(1):186-94.
309.Krzysiek R, Lefevre EA, Bernard J, Foussat A, Galanaud P, Louache F, et al. Regulation of
CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory
protein-3alpha/CCL20 in human B cells. Blood. 2000;96(7):2338-45.
310.Wang C, Kang SG, Lee J, Sun Z, Kim CH. The roles of CCR6 in migration of Th17 cells
and regulation of effector T-cell balance in the gut. Mucosal Immunol. 2009;2(2):173-83.
311.Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune
cells. Annu Rev Immunol. 2003;21:107-37.
312.Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ. CD45: new jobs for an old
acquaintance. Nat Immunol. 2001;2(5):389-96.
313.Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common
tyrosine phosphatase, CD45. Cell Signal. 2010;22(3):339-48.
314.Thomas RM, Schmedt C, Novelli M, Choi BK, Skok J, Tarakhovsky A, et al. C-terminal SRC
kinase controls acute inflammation and granulocyte adhesion. Immunity. 2004;20(2):181-
91.
315.Shivtiel S, Lapid K, Kalchenko V, Avigdor A, Goichberg P, Kalinkovich A, et al. CD45
regulates homing and engraftment of immature normal and leukemic human cells in
transplanted immunodeficient mice. Exp Hematol. 2011;39(12):1161-70 e1.
316.Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev
Dyn. 2000;218(2):213-34.
317.Rousselle P, Lunstrum GP, Keene DR, Burgeson RE. Kalinin: an epithelium-specific
basement membrane adhesion molecule that is a component of anchoring filaments. J Cell
Biol. 1991;114(3):567-76.
318.Gu YC, Kortesmaa J, Tryggvason K, Persson J, Ekblom P, Jacobsen SE, et al. Laminin
isoform-specific promotion of adhesion and migration of human bone marrow progenitor
cells. Blood. 2003;101(3):877-85.
319.Siler U, Seiffert M, Puch S, Richards A, Torok-Storb B, Muller CA, et al. Characterization
and functional analysis of laminin isoforms in human bone marrow. Blood.
2000;96(13):4194-203.
320.Kutlesa S, Siler U, Speiser A, Wessels JT, Virtanen I, Rousselle P, et al. Developmentally
regulated interactions of human thymocytes with different laminin isoforms. Immunology.
2002;105(4):407-18.
321.Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. Characterization and
partial purification of human marrow cells capable of initiating long-term hematopoiesis in
vitro. Blood. 1989;74(5):1563-70.
322.Dick JE, Bhatia M, Gan O, Kapp U, Wang JC. Assay of human stem cells by repopulation
of NOD/SCID mice. Stem Cells. 1997;15 Suppl 1:199-203; discussion 4-7.
323.Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, et al. The metastasisassociated
67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell
mobilization. Blood. 2006;108(7):2476-84.
324.Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6.
Cytokine Growth Factor Rev. 2003;14(5):409-26.
325.Ito T, Carson WFt, Cavassani KA, Connett JM, Kunkel SL. CCR6 as a mediator of immunity
in the lung and gut. Exp Cell Res. 2011;317(5):613-9.
326.Lee AY, Eri R, Lyons AB, Grimm MC, Korner H. CC Chemokine Ligand 20 and Its Cognate
Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd
Couple or Axis of Evil? Front Immunol. 2013;4:194.
327.Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, et al. CCR6 regulates
the migration of inflammatory and regulatory T cells. J Immunol. 2008;181(12):8391-401.
328.Reinsch S, Gonczy P. Mechanisms of nuclear positioning. J Cell Sci. 1998;111 ( Pt
16):2283-95.
329.Burke B, Roux KJ. Nuclei take a position: managing nuclear location. Dev Cell.
2009;17(5):587-97.
330.Gomes ER, Jani S, Gundersen GG. Nuclear movement regulated by Cdc42, MRCK,
myosin, and actin flow establishes MTOC polarization in migrating cells. Cell.
2005;121(3):451-63.
331.Dupin I, Camand E, Etienne-Manneville S. Classical cadherins control nucleus and
centrosome position and cell polarity. J Cell Biol. 2009;185(5):779-86.
332.Bellion A, Baudoin JP, Alvarez C, Bornens M, Metin C. Nucleokinesis in tangentially
migrating neurons comprises two alternating phases: forward migration of the
Golgi/centrosome associated with centrosome splitting and myosin contraction at the rear.
J Neurosci. 2005;25(24):5691-9.
333.Luxton GW, Gomes ER, Folker ES, Vintinner E, Gundersen GG. Linear arrays of nuclear
envelope proteins harness retrograde actin flow for nuclear movement. Science.
2010;329(5994):956-9.
334.Starr DA, Fridolfsson HN. Interactions between nuclei and the cytoskeleton are mediated
by SUN-KASH nuclear-envelope bridges. Annu Rev Cell Dev Biol. 2010;26:421-44.
335.Martins RP, Finan JD, Guilak F, Lee DA. Mechanical regulation of nuclear structure and
function. Annu Rev Biomed Eng. 2012;14:431-55.
336.Simon DN, Wilson KL. The nucleoskeleton as a genome-associated dynamic 'network of
networks'. Nat Rev Mol Cell Biol. 2011;12(11):695-708.
337.Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol.
2009;10(1):63-73.
338.Lombardi ML, Jaalouk DE, Shanahan CM, Burke B, Roux KJ, Lammerding J. The
interaction between nesprins and sun proteins at the nuclear envelope is critical for force
transmission between the nucleus and cytoskeleton. J Biol Chem. 2011;286(30):26743-53.
339.Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, et al. Nesprins: a novel
family of spectrin-repeat-containing proteins that localize to the nuclear membrane in
multiple tissues. J Cell Sci. 2001;114(Pt 24):4485-98.
340.Folker ES, Ostlund C, Luxton GW, Worman HJ, Gundersen GG. Lamin A variants that
cause striated muscle disease are defective in anchoring transmembrane actin-associated
nuclear lines for nuclear movement. Proc Natl Acad Sci U S A. 2011;108(1):131-6.
341.Borrego-Pinto J, Jegou T, Osorio DS, Aurade F, Gorjanacz M, Koch B, et al. Samp1 is a
component of TAN lines and is required for nuclear movement. J Cell Sci. 2012;125(Pt
5):1099-105.
342.Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, et al. Sonic hedgehog
induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat
Immunol. 2001;2(2):172-80.
343.Ingham PW. Transducing Hedgehog: the story so far. EMBO J. 1998;17(13):3505-11.
344.Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature.
2001;411(6835):349-54.
345.Chiba S. Notch signaling in stem cell systems. Stem Cells. 2006;24(11):2437-47.
346.Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal
integration in development. Science. 1999;284(5415):770-6.
347.Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis:
evidence and speculation. Blood. 1999;93(8):2431-48.
348.Aster JC, Pear WS. Notch signaling in leukemia. Curr Opin Hematol. 2001;8(4):237-44.
349.Karanu FN, Murdoch B, Miyabayashi T, Ohno M, Koremoto M, Gallacher L, et al. Human
homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human
hematopoietic cells. Blood. 2001;97(7):1960-7.
350.Suzuki T, Yokoyama Y, Kumano K, Takanashi M, Kozuma S, Takato T, et al. Highly efficient
ex vivo expansion of human hematopoietic stem cells using Delta1-Fc chimeric protein.
Stem Cells. 2006;24(11):2456-65.
351.Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al. Transplantation
of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a
phase I/II clinical trial. Bone Marrow Transplant. 2008;41(9):771-8.
352.Varnum-Finney B, Brashem-Stein C, Bernstein ID. Combined effects of Notch signaling and
cytokines induce a multiple log increase in precursors with lymphoid and myeloid
reconstituting ability. Blood. 2003;101(5):1784-9.
353.Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dose-dependent
effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating
ability of cord blood cells. Blood. 2005;106(8):2693-9.
354.Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus
repopulating ability of human CD34(+)CD38(-) cord blood cells. J Clin Invest.
2002;110(8):1165-74.
355.Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notchmediated
expansion of human cord blood progenitor cells capable of rapid myeloid
reconstitution. Nat Med. 2010;16(2):232-6.
356.Dumortier A, Wilson A, MacDonald HR, Radtke F. Paradigms of notch signaling in
mammals. Int J Hematol. 2005;82(4):277-84.
357.Bolos V, Mira E, Martinez-Poveda B, Luxan G, Canamero M, Martinez AC, et al. Notch
activation stimulates migration of breast cancer cells and promotes tumor growth. Breast
Cancer Res. 2013;15(4):R54.
358.Lefort K, Dotto GP. Notch signaling in the integrated control of keratinocyte
growth/differentiation and tumor suppression. Semin Cancer Biol. 2004;14(5):374-86.
359.Koster MI, Roop DR. The role of p63 in development and differentiation of the epidermis. J
Dermatol Sci. 2004;34(1):3-9.
360.Verónica Fernández-Sánchez, Rosana Pelayo, Patricia Flores-Guzmán, Eugenia Flores-
Figueroa, Jairo Villanueva-Toledo, Efraín Garrido, Elizbeth Álvarez-Sánchez. Elizabeth
Ruiz-Sánchez, Héctor Mayani. In vitro effects of stromal cells expressing different levels of
Jagged-1 and delta-1 on the growth of primitive and intermediate CD34+ cell subsets from
human cord blood. Blood Cells, Molecules, and diseases. 2011. 47:205-213.
361.McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev.
2004;18(5):465-9.
362.Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Crossregulation
between Notch and p63 in keratinocyte commitment to differentiation. Genes
Dev. 2006;20(8):1028-42.
363.Yalcin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Brisken C. Antagonistic
roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ.
2010;17(10):1600-12.
364.Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, Plymoth A, et al. Recent advances
in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009;16(1):1-12.
365.Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes.
Nat Rev Mol Cell Biol. 2008;9(5):402-12.
366.Jerry DJ, Tao L, Yan H. Regulation of cancer stem cells by p53. Breast Cancer Res.
2008;10(4):304.
367.Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, et al. Identification of
tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res.
2008;68(12):4674-82.
368.Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control
neural and glioma stem/progenitor cell renewal and differentiation. Nature.
2008;455(7216):1129-33.
369.Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue
required for limb and epidermal morphogenesis. Nature. 1999;398(6729):708-13.
370.Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for
regenerative proliferation in limb, craniofacial and epithelial development. Nature.
1999;398(6729):714-8.
371.Madihally SV, Flake AW, Matthew HW. Maintenance of CD34 expression during
proliferation of CD34+ cord blood cells on glycosaminoglycan surfaces. Stem Cells.
1999;17(5):295-305.
372.Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, Nusse R, et al. Wnt signaling
regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity.
2000;13(1):15-24.
373.Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol.
1998;14:59-88.
374.Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling
in self-renewal of haematopoietic stem cells. Nature. 2003;423(6938):409-14.
375.Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocytemacrophage
progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J
Med. 2004;351(7):657-67.
376.Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, et al. Wnt-1 signaling inhibits
apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol.
2001;152(1):87-96.
377.Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal
and regeneration: Wnt signaling and stem cell control. Science. 2014;346(6205):1248012.
378.Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol.
2012;13(12):767-79.
379.Yang K, Wang X, Zhang H, Wang Z, Nan G, Li Y, et al. The evolving roles of canonical
WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies.
Lab Invest. 2016;96(2):116-36.
380.Ivan A, Azoicai D, Stefanache F, Manole A, Hodorog D, Trifan M, et al. [Prospective
epidemiologic and clinical observations on the prevalence of risk factors for stroke,
performed on 374 inpatients, during the period of June 2001-June 2004]. Rev Med Chir Soc
Med Nat Iasi. 2004;108(3):561-5.
381.Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, et al. Integration
of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol.
2005;6(3):314-22.
382.Galceran J, Sustmann C, Hsu SC, Folberth S, Grosschedl R. LEF1-mediated regulation of
Delta-like1 links Wnt and Notch signaling in somitogenesis. Genes Dev. 2004;18(22):2718-
23.
383.Collu GM, Hidalgo-Sastre A, Brennan K. Wnt-Notch signalling crosstalk in development and
disease. Cell Mol Life Sci. 2014;71(18):3553-67.
384.Munoz-Descalzo S, de Navascues J, Arias AM. Wnt-Notch signalling: an integrated
mechanism regulating transitions between cell states. Bioessays. 2012;34(2):110-8.
385.Hayward P, Brennan K, Sanders P, Balayo T, DasGupta R, Perrimon N, et al. Notch
modulates Wnt signalling by associating with Armadillo/beta-catenin and regulating its
transcriptional activity. Development. 2005;132(8):1819-30.
386.Axelrod JD, Matsuno K, Artavanis-Tsakonas S, Perrimon N. Interaction between Wingless
and Notch signaling pathways mediated by dishevelled. Science. 1996;271(5257):1826-32.
387.Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, et al. MSX1 induces
the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. Cancer Lett.
2010;289(2):195-207.
388.Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1 activation involves
Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell.
2006;98(8):479-90.
389.Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, et al. Initiation of Wnt signaling:
control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin
functions. Development. 2008;135(2):367-75.
390.Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and
disease. Development. 2014;141(8):1614-26.
391.Hansen CG, Moroishi T, Guan KL. YAP and TAZ: a nexus for Hippo signaling and beyond.
Trends Cell Biol. 2015;25(9):499-513.
392.Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell
Biol. 2012;22(7):339-46.
393.Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of
intestinal stem cell expansion and the regenerative response by YAP. Nature.
2013;493(7430):106-10.
394.Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, et al. Hippo pathway
inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science.
2011;332(6028):458-61.
395.Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation
in the beta-catenin destruction complex orchestrates the Wnt response. Cell.
2014;158(1):157-70.
396.Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, et al. Alternative Wnt Signaling
Activates YAP/TAZ. Cell. 2015;162(4):780-9
397.Coons SJ. The FDA's critical path initiative: a brief introduction. Clin Ther.
2009;31(11):2572-3
398.Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray
Quality Control (MAQC)-II study of common practices for the development and validation of
microarray-based predictive models. Nat Biotechnol. 2010;28(8):827-38.
399.Haddadin RD. Concept of biosimilar products in Jordan. Biologicals. 2011;39(5):333-5.
400.Food, Drug Administration HHS. International Conference on Harmonisation; guidance on
Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their
Manufacturing Process; availability. Notice. Fed Regist. 2005;70(125):37861-2.
401.Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of
extrapolation. Blood. 2014;124(22):3191-6.
402.Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, et al. Granulocyte- and
granulocyte-macrophage-colony stimulating factors induce human endothelial cells to
migrate and proliferate. Nature. 1989;337(6206):471-3.
403.Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a
novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord
blood. Blood. 2004;104(9):2752-60.
404.Flynn A, Barry F, O'Brien T. UC blood-derived mesenchymal stromal cells: an overview.
Cytotherapy. 2007;9(8):717-26.
405.Luz Mabel ávila Portillo, Benjamín Ospino, Carlos A. Franco, Francisco Arroyo. Efectos del
uso del factor estimulante de colonias granulocíticas en la obtención de células madre en
un grupo de pacientes con enfermedad arterial oclusiva crónica. Rev. Colomb. Cienc.
Quím. Farm., 2010; 39(2):122-131
406.LM Ávila Portillo, C. Torres Triviño, LF Ponce, D’Leon Y. Baena, FA Aristizábal. Las células
madre, piedra angular de rejuvenecimiento. Aclarando conceptos Stem cells. Med Cutan
Iber Lat Am .2012;40(1):3-10.
407.Luz Mábel Ávila-Portillo, José I. Madero, Claudia López, María Fernanda León, Lucía
Acosta, Claudia Gómez, Lucy Gabriela Delgado, Claudio Gómez, José Manuel Lozano,
María T. Reguero. Fundamentos de Criopreservación. Revista Colombiana de Obstetricia
y Ginecología.2006; (57) No. 4: 291-300. | |
